Membrane Proteins Screening Array-AB5000
KYinno Unveils the AB5000 Membrane Protein Engineering Patent Technology Screening Platform
Antibodies, CAR-T cells, and other biopharmaceuticals rely on the specificity of their target binding, which is a critical factor in assessing the quality of these drugs, particularly in membrane protein antibody discovery where off-target interactions are harder to predict. Non-specific binding of these drugs to proteins or molecules outside their intended target can lead to severe side effects. Therefore, specificity testing is a vital evaluation step in drug development. In addition to binding analysis, functional evaluation methods such as ADCC & ADCP Assays are commonly used to assess immune-mediated mechanisms that may influence therapeutic efficacy and safety. Currently, many antibody drugs only verify non-specific binding in clinical trials, and this delay may lead to safety issues and the abandonment of earlier research. For instance, the FDA-approved anti-PD-1 monoclonal antibody was found to have non-specific binding to VEGFR2, leading to severe side effects such as hemangioma. Interestingly, the ADC drug Rova-T, which cost AbbVie $5.6 billion, performed poorly in clinical trials. Recently, our AB5000 screening platform identified non-specific binding of the DLL3 antibody to other important immune targets, which may have implications for clinical efficacy.



Case Study
The off-target binding of anti-PD1 monoclonal antibody “SHR-1210” to VEGFR2, FZD5, ULBP2 leads to serious side effects such as capillary hemangioma. AB5000 membrane protein engineering screening platform can effectively screen non-specific binding sites.
1. Experimental platform establishment
2. Target Screening
Figure 3. Body Weight of NCI-H1975-HGF in Female NOD SCID mice.